Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO’s elimination strategy

Table 2 Infrastructure for HBV testing/treatment in Madagascar in 2016

		Total number	No. of facilities in the capital region (Antananarivo)		No. of facilities in other regions		Price
		Total number	Public	Private	Public	Private	Price
1. Screening for HBV
HBsAg assay	ELISA	3	2	1	0	0	$ 10
HBsAg assay	Point-of-care test	74	11	22	29	12	$ 2–5
2. Clinical staging
AST & ALT		77	13	23	29	12	$ 2–5
HBV DNA PCR assay		0	0	0	0	0	N/A
Fibroscan®		0	0	0	0	0	N/A
Hepatologist		5	3	0	2	0	N/A
3. Treatment
HBV treatment	Lamivudine	1	0	1	0	0	$ 0.7/dose
HBV treatment	Tenofovir	0	0	0	0	0	N/A

Abbreviations: ELISA enzyme-linked immunosorbent assay, N/A not applicable

ISSN: 1471-2458